This article is more than 5 years old. Information may no longer be current.
New circulating tumor cell assay in development
Click Here to Manage Email Alerts
A collaborative effort by Veridex LLC, Massachusetts General Hospital and Ortho Biotech Oncology Research and Development will result in the development of a next-generation circulating tumor cell technology that will capture, count and characterize tumor cells in patients’ blood. The technology will be available as an oncology diagnostic tool and will enhance the process of drug discovery and development, according to a press release.
The platform will be a bench-top system that isolates and explores the biology of rare cells at the protein, RNA and DNA levels.
“The challenging goal of sorting extremely rare circulating tumor cells from blood requires continuous technological, biological and clinical innovation to fully explore the utility of these precious cells in clinical oncology,” Mehmet Toner, PhD, director of the BioMicroElectroMechanical System Resource Center in the Massachusetts General Hospital Center for Engineering in Medicine, said in the press release. “We have developed and continue to develop a broad range of technologies that are evolving what we know about cancer and cancer care. This collaboration is an opportunity to apply our past learning to the advancement of a platform that will ultimately benefit patients with cancer.”
According to the release, Veridex will guide the clinical validation and regulatory submissions for future diagnostic applications of the new technology. The company developed the first commercial circulating tumor cell test in 2004.
 |
Follow HemOncToday.com on Twitter. |